Takeda
Takeda’s breast cancer treatment approved in Scotland
February 9, 2021Manufacturing and Production Takeda, breast cancer
The Scottish Medicines Consortium has accepted Takeda’s PROSTAP 3 DCS (leuprorelin acetate) treatment for use in patients with early and …
NICE authorises Takeda’s Alunbrig for ALK-positive advanced non-small cell lung cancer
December 10, 2020Sales and Marketing ALK-positive advanced non-small cell lung cancer, Alunbrig, NICE, Takeda
NICE has published its final appraisal of Takeda’s Alunbrig (brigatinib), recommending the therapy for the treatment of ALK-positive advanced non-small …
China approves Takeda’s Takhzyro to prevent hereditary angioedema attacks in patients over 12
December 8, 2020Manufacturing and Production, Sales and Marketing China, Takeda
China’s National Medical Products Administration (NMPA) has given approval in the country for Takeda’s Takhzyro (lanadelumab), in a subcutaneous injection …
Cabometyx scores Japanese approval for unresectable hepatocellular carcinoma patients following systemic therapy
November 30, 2020Sales and Marketing Cabometyx, Japan, Takeda
The Japanese Ministry of Health, Labor and Welfare has awarded approval to Takeda for Cabometyx (cabozantinib) as a treatment for …
Takeda commits to deliver 50 million doses of Moderna’s COVID-19 vaccine in Japan
October 29, 2020Manufacturing and Production, Sales and Marketing COVID-19, Japan, Moderna, Takeda, Vaccine
Takeda has made a commitment with Japan’s Ministry of Health, Labor and Welfare (MHLW) to deliver 50 million doses of …
Takeda and Arrowhead Pharma join forces in $1m rare liver disease drug development pact
October 9, 2020Medical Communications, Research and Development Arrowhead, Takeda, pharma
A new partnership has been struck between Takeda and Arrowhead Pharmaceuticals, with both companies coming together to co-develop and license …
Takeda to sell another non-core portfolio for $260 million to Cheplapharm
September 8, 2020Manufacturing and Production, Sales and Marketing Cheplapharm, Takeda, pharma
Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an …
Takeda poised to cut sales jobs in Japan as restructuring continues
July 29, 2020Medical Communications, Research and Development, Sales and Marketing Japan, Takeda, job cuts
Japan’s biggest drug firm Takeda is said to be mulling plans to cut back its sales operations with a new …
NICE recommends Takeda’s Adcetris for previously untreated systemic anaplastic large cell lymphoma
July 9, 2020Sales and Marketing Adcentris, NICE, Takeda, UK
NICE has announced it has recommended Takeda’s Adcetris (brentuximab vedotin), in combination with cyclophosphamide, doxorubicin and prednisone (CHP), for use …
Takeda jettisons non-core portfolio in Asia Pacific to Celltrion for a potential $278 million
June 12, 2020Medical Communications, Sales and Marketing Takeda, celltrion, pharma, sale
Takeda continues its mission to reduce its debt in the wake of its $49 billion acquisition of Shire in January …
FDA approves Takeda’s first-line treatment option for non-small cell lung cancer
May 26, 2020Manufacturing and Production FDA, Takeda, approval
The FDA has approved Takeda’s Alunbrig (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer …
Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis
May 11, 2020Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis
The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …
Takeda’s Alunbrig outclasses Xalkori to secure EU approval in ALK+ advanced non-small cell lung cancer
April 7, 2020Manufacturing and Production, Sales and Marketing Alunbrig, Europe, Takeda, pharma
The European Commission has ruled to expand the current approved indication of Takeda’s Alunbrig (brigatinib), authorising the drug as a …
China approves Takeda’s treatment for ulcerative colitis and Crohn’s disease
March 24, 2020Manufacturing and Production Crohn's, Takeda, Takeda China
China’s National Medical Products Administration (NMPA) has approved Takeda’s Entyvio (vedolizumab) for the treatment of adult patients with ulcerative colitis …
Takeda’s Ninlaro combo fails to hit main goal in newly diagnosed, transplant ineligible multiple myeloma
March 11, 2020Research and Development, Sales and Marketing Ninlaro, Takeda, multiple myeloma, pharma
Takeda has unveiled new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib) in the treatment of newly diagnosed …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
